Anton Y. Peleg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3494766/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Feasibility of Bluetooth Low Energy wearable tags to quantify healthcare worker proximity networks and patient close contact: A pilot study. Infection, Disease and Health, 2022, 27, 66-70.	1.1	9
2	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0220321.	3.2	4
3	Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection <i>in vitro</i> model. Journal of Antimicrobial Chemotherapy, 2022, 77, 1324-1333.	3.0	6
4	Epidemiology, antimicrobial resistance and outcomes of Staphylococcus aureus bacteraemia in a tertiary hospital in Fiji: A prospective cohort study. The Lancet Regional Health - Western Pacific, 2022, 22, 100438.	2.9	8
5	Genomic and phenotypic analyses of diverse non-clinical Acinetobacter baumannii strains reveals strain-specific virulence and resistance capacity. Microbial Genomics, 2022, 8, .	2.0	7
6	Mpeg1 is not essential for antibacterial or antiviral immunity, but is implicated in antigen presentation. Immunology and Cell Biology, 2022, 100, 529-546.	2.3	4
7	Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine, 2022, 80, 104045.	6.1	40
8	Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients. Journal of Heart and Lung Transplantation, 2022, 41, 1258-1267.	0.6	6
9	Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2022, 75, 1848-1860.	5.8	39
10	Search and Contain: Impact of an Integrated Genomic and Epidemiological Surveillance and Response Program for Control of Carbapenemase-producing <i>Enterobacterales</i> . Clinical Infectious Diseases, 2021, 73, e3912-e3920.	5.8	12
11	Treatment of invasive IMPâ€4 <i>Enterobacter cloacae</i> infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review. Transplant Infectious Disease, 2021, 23, e13510.	1.7	20
12	Evaluation of Quantiferon®â€Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients. Transplant Infectious Disease, 2021, 23, e13550.	1.7	13
13	Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections. Expert Review of Anti-Infective Therapy, 2021, 19, 271-295.	4.4	5
14	Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials. Nature Microbiology, 2021, 6, 157-161.	13.3	159
15	The Resistance to Host Antimicrobial Peptides in Infections Caused by Daptomycin-Resistant Staphylococcus aureus. Antibiotics, 2021, 10, 96.	3.7	6
16	Multicentre stepped-wedge cluster randomised controlled trial of an antimicrobial stewardship programme in residential aged care: protocol for the START trial. BMJ Open, 2021, 11, e046142.	1.9	2
17	Silent spread of mobile colistin resistance gene mcr-9.1 on IncHI2 â€~superplasmids' in clinical carbapenem-resistant Enterobacterales. Clinical Microbiology and Infection, 2021, 27, 1856.e7-1856.e13.	6.0	37
18	The Membrane Composition Defines the Spatial Organization and Function of a Major Acinetobacter baumannii Drug Efflux System. MBio, 2021, 12, e0107021.	4.1	14

#	Article	IF	CITATIONS
19	Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints. Journal of Antimicrobial Chemotherapy, 2021, 76, 3201-3211.	3.0	3
20	Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Journal of Global Antimicrobial Resistance, 2021, 26, 55-63.	2.2	7
21	<i>Staphylococcus aureus</i> entanglement in self-assembling β-peptide nanofibres decorated with vancomycin. Nanoscale Advances, 2021, 3, 2607-2616.	4.6	6
22	Ventricular Assist Device-Specific Infections. Journal of Clinical Medicine, 2021, 10, 453.	2.4	14
23	Antibiotic-chemoattractants enhance neutrophil clearance of Staphylococcus aureus. Nature Communications, 2021, 12, 6157.	12.8	18
24	178. Endemic Carbapenem Resistance Driven By Clonal and Horizontal Spread of <i>bla</i> IMP-4 Across Diverse Enterobacterales: Jumping Genes, Promiscuous Plasmids and Killer Clones. Open Forum Infectious Diseases, 2021, 8, S109-S109.	0.9	0
25	Biofilm formation and migration on ventricular assist device drivelines. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 491-502.e2.	0.8	23
26	Daptomycinâ€resistant <i>Staphylococcus aureus</i> clinical isolates are poorly sensed by dendritic cells. Immunology and Cell Biology, 2020, 98, 42-53.	2.3	5
27	Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 988-996.	3.0	13
28	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales : the Importance of Heteroresistance for Growth Outcome. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
29	An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 847.	1.6	6
30	Characterization of infected, explanted ventricular assist device drivelines: The role of biofilms and microgaps in the driveline tunnel. Journal of Heart and Lung Transplantation, 2020, 39, 1289-1299.	0.6	9
31	In vitro Evaluation of Medihoney Antibacterial Wound Gel as an Anti-biofilm Agent Against Ventricular Assist Device Driveline Infections. Frontiers in Microbiology, 2020, 11, 605608.	3.5	2
32	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	11.9	244
33	Efficacy of single and multiple oral doses of fosfomycin against Pseudomonas aeruginosa urinary tract infections in a dynamic in vitro bladder infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 1879-1888.	3.0	9
34	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
35	Antimicrobial resistance in the Pacific Island countries and territories. BMJ Global Health, 2020, 5, e002418.	4.7	17
36	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	19

#	Article	IF	CITATIONS
37	Rapid Approach for Detection of Antibiotic Resistance in Bacteria Using Vibrational Spectroscopy. Analytical Chemistry, 2020, 92, 8235-8243.	6.5	13
38	Ushering in Antifungal Stewardship: Perspectives of the Hematology Multidisciplinary Team Navigating Competing Demands, Constraints, and Uncertainty. Open Forum Infectious Diseases, 2020, 7, ofaa168.	0.9	4
39	Predicting Phenotypic Polymyxin Resistance in Klebsiella pneumoniae through Machine Learning Analysis of Genomic Data. MSystems, 2020, 5, .	3.8	35
40	Hyperosmotic Infusion and Oxidized Surfaces Are Essential for Biofilm Formation of Staphylococcus capitis From the Neonatal Intensive Care Unit. Frontiers in Microbiology, 2020, 11, 920.	3.5	11
41	Targeting NLRP3 and Staphylococcal pore-forming toxin receptors in human-induced pluripotent stem cell-derived macrophages. Journal of Leukocyte Biology, 2020, 108, 967-981.	3.3	19
42	An audit of nitrofurantoin use in three Australian hospitals. Infection, Disease and Health, 2020, 25, 124-129.	1.1	1
43	Vibrational Spectroscopy as a Sensitive Probe for the Chemistry of Intra-Phase Bacterial Growth. Sensors, 2020, 20, 3452.	3.8	16
44	Insufficient plasma concentrations of empiric antiâ€pseudomonal betaâ€lactam antibiotics in critically ill patients with suspected sepsis. Journal of Pharmacy Practice and Research, 2020, 50, 345-350.	0.8	0
45	Staphylococcus aureus induces cell-surface expression of immune stimulatory NKG2D ligands on human monocytes. Journal of Biological Chemistry, 2020, 295, 11803-11821.	3.4	10
46	Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection. Scientific Reports, 2020, 10, 1459.	3.3	7
47	Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. Journal of Microbiological Methods, 2020, 171, 105861.	1.6	15
48	Influence of the Sample Preparation Method in Discriminating Candida spp. Using ATR-FTIR Spectroscopy. Molecules, 2020, 25, 1551.	3.8	13
49	A mouse model of Staphylococcus aureus small intestinal infection. Journal of Medical Microbiology, 2020, 69, 290-297.	1.8	15
50	Atomic Force Microscopy Combined with Infrared Spectroscopy as a Tool to Probe Single Bacterium Chemistry. Journal of Visualized Experiments, 2020, , .	0.3	4
51	Pooled Plasmid Sequencing Reveals the Relationship Between Mobile Genetic Elements and Antimicrobial Resistance Genes in Clinically Isolated Klebsiella pneumoniae. Genomics, Proteomics and Bioinformatics, 2020, 18, 539-548.	6.9	17
52	Spectrum of illness among returned Australian travellers from Bali, Indonesia: a 5â€year retrospective observational study. Internal Medicine Journal, 2019, 49, 34-40.	0.8	11
53	Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
54	The Mechanisms of Disease Caused by Acinetobacter baumannii. Frontiers in Microbiology, 2019, 10, 1601.	3.5	220

#	Article	IF	CITATIONS
55	A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity. Nature Communications, 2019, 10, 3392.	12.8	40
56	Closing the Gap in Surveillance and Audit of Invasive Mold Diseases for Antifungal Stewardship Using Machine Learning. Journal of Clinical Medicine, 2019, 8, 1390.	2.4	12
57	Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles. Current Infectious Disease Reports, 2019, 21, 26.	3.0	10
58	Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Australian Prescriber, 2019, 42, 14.	1.0	87
59	Identification of Novel <i>Acinetobacter baumannii</i> Host Fatty Acid Stress Adaptation Strategies. MBio, 2019, 10, .	4.1	43
60	Antibiotic resistance and host immune evasion in <i>Staphylococcus aureus</i> mediated by a metabolic adaptation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3722-3727.	7.1	69
61	Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
62	Unstable chromosome rearrangements in <i>Staphylococcus aureus</i> cause phenotype switching associated with persistent infections. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20135-20140.	7.1	69
63	Detection of Antimicrobial Resistance-Related Changes in Biochemical Composition of <i>Staphylococcus aureus</i> by Means of Atomic Force Microscopy-Infrared Spectroscopy. Analytical Chemistry, 2019, 91, 15397-15403.	6.5	20
64	Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	22
65	OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	47
66	Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. Journal of Antimicrobial Chemotherapy, 2018, 73, 1570-1578.	3.0	21
67	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
68	Convergent Evolution Driven by Rifampin Exacerbates the Global Burden of Drug-Resistant Staphylococcus aureus. MSphere, 2018, 3, .	2.9	55
69	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. Journal of Antimicrobial Chemotherapy, 2018, 73, 709-719.	3.0	30
70	<i>In vivo</i> atomic force microscopy–infrared spectroscopy of bacteria. Journal of the Royal Society Interface, 2018, 15, 20180115.	3.4	60
71	Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition. Journal of Cystic Fibrosis, 2018, 17, 50-56.	0.7	37
72	1551. The Impact of Recurrent CMV Disease on Long-Term Survival in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2018, 5, S481-S482.	0.9	1

#	Article	IF	CITATIONS
73	1386. Efficacy of Repeat Dosing of Oral Fosfomycin in a Dynamic Bladder Infection In Vitro Model. Open Forum Infectious Diseases, 2018, 5, S425-S425.	0.9	0
74	Comprehensive antibiotic-linked mutation assessment by resistance mutation sequencing (RM-seq). Genome Medicine, 2018, 10, 63.	8.2	26
75	Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	26
76	Structural Basis for Linezolid Binding Site Rearrangement in the <i>Staphylococcus aureus</i> Ribosome. MBio, 2017, 8, .	4.1	37
77	Synthesis of novel 1,2,5-oxadiazoles and evaluation of action against Acinetobacter baumannii. Bioorganic and Medicinal Chemistry, 2017, 25, 6267-6272.	3.0	16
78	Donor-Derived Mycoplasma hominis and an Apparent Cluster of M. hominis Cases in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2017, 65, 1504-1508.	5.8	34
79	Optimizing Microplate Biofilm Assays to Screen Anti-infective Surfaces. Trends in Biotechnology, 2017, 35, 3-5.	9.3	5
80	Antibiotic regimen based on population analysis of residing persister cells eradicates Staphylococcus epidermidis biofilms. Scientific Reports, 2016, 5, 18578.	3.3	31
81	Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of <i>Pseudomonas aeruginosa</i> , but do not suppress the emergence of fosfomycin resistance. Journal of Antimicrobial Chemotherapy, 2016, 71, 2218-2229.	3.0	32
82	<i>Acinetobacter baumannii</i> phenylacetic acid metabolism influences infection outcome through a direct effect on neutrophil chemotaxis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9599-9604.	7.1	109
83	Polymicrobial infections involving clinically relevant Gram-negative bacteria and fungi. Cellular Microbiology, 2016, 18, 1716-1722.	2.1	33
84	Vancomycin susceptibility in methicillin-resistant Staphylococcus aureus is mediated by YycHI activation of the WalRK essential two-component regulatory system. Scientific Reports, 2016, 6, 30823.	3.3	48
85	Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology. Antimicrobial Agents and Chemotherapy, 2016, 60, 161-167.	3.2	40
86	Anti-infective Surface Coatings: Design and Therapeutic Promise against Device-Associated Infections. PLoS Pathogens, 2016, 12, e1005598.	4.7	43
87	Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Current Opinion in Infectious Diseases, 2015, 28, 547-556.	3.1	67
88	Active surveillance for multidrug-resistant Gram-negative bacteria in the intensive care unit. Pathology, 2015, 47, 575-579.	0.6	7
89	Distribution of β-Lactamase Genes Among Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Strains Isolated From Patients in Turkey. Annals of Laboratory Medicine, 2015, 35, 595-601.	2.5	41
90	Insights on virulence from the complete genome of Staphylococcus capitis. Frontiers in Microbiology, 2015, 6, 980.	3.5	56

#	Article	IF	CITATIONS
91	Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin. Genes, 2015, 6, 1256-1267.	2.4	13
92	Impact of daptomycin resistance on <i>Staphylococcus aureus</i> virulence. Virulence, 2015, 6, 127-131.	4.4	31
93	Surface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens. Journal of Materials Chemistry B, 2015, 3, 8469-8476.	5.8	31
94	Differentiation of Acinetobacter Genomic Species 13BJ/14TU from Acinetobacter haemolyticus by Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry (MALDI-TOF MS): TABLE 1. Journal of Clinical Microbiology, 2015, 53, 3384-3386.	3.9	7
95	Stenotrophomonas, Achromobacter, and Nonmelioid Burkholderia Species: Antimicrobial Resistance and Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 099-110.	2.1	94
96	Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 085-098.	2.1	233
97	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	1.6	57
98	Use of portable electronic devices in a hospital setting and their potential for bacterial colonization. American Journal of Infection Control, 2015, 43, 286-288.	2.3	20
99	Community-acquired <i>Acinetobacter baumannii</i> : clinical characteristics, epidemiology and pathogenesis. Expert Review of Anti-Infective Therapy, 2015, 13, 567-573.	4.4	150
100	The influence of bacterial interaction on the virulence of <i>Cryptococcus neoformans</i> . Virulence, 2015, 6, 677-678.	4.4	9
101	Species identification within Acinetobacter calcoaceticus–baumannii complex using MALDI-TOF MS. Journal of Microbiological Methods, 2015, 118, 128-132.	1.6	22
102	<i>In vitro</i> pharmacodynamics of fosfomycin against clinical isolates of <i>Pseudomonas aeruginosa</i> . Journal of Antimicrobial Chemotherapy, 2015, 70, 3042-3050.	3.0	72
103	Identification of a Class of Protein ADP-Ribosylating Sirtuins in Microbial Pathogens. Molecular Cell, 2015, 59, 309-320.	9.7	79
104	Stepwise Decrease in Daptomycin Susceptibility in Clinical Staphylococcus aureus Isolates Associated with an Initial Mutation in <i>rpoB</i> and a Compensatory Inactivation of the <i>clpX</i> Gene. Antimicrobial Agents and Chemotherapy, 2015, 59, 6983-6991.	3.2	74
105	Antibiotic prescribing practice in residential aged care facilities ―health care providers' perspectives. Medical Journal of Australia, 2014, 201, 101-105.	1.7	20
106	Antibiotic prescribing practice in residential aged care facilities — health care providers' perspectives. Medical Journal of Australia, 2014, 201, 574-574.	1.7	36
107	The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infection, Genetics and Evolution, 2014, 21, 575-582.	2.3	115
108	A Global Virulence Regulator in Acinetobacter baumannii and Its Control of the Phenylacetic Acid Catabolic Pathway. Journal of Infectious Diseases, 2014, 210, 46-55.	4.0	139

#	Article	IF	CITATIONS
109	Antimicrobial stewardship in residential aged care facilities: need and readiness assessment. BMC Infectious Diseases, 2014, 14, 410.	2.9	37
110	Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1972-1980.	3.0	106
111	Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control study. BMC Infectious Diseases, 2014, 14, 126.	2.9	29
112	Population genetics and the evolution of virulence in Staphylococcus aureus. Infection, Genetics and Evolution, 2014, 21, 554-562.	2.3	32
113	The RpoB H481Y Rifampicin Resistance Mutation and an Active Stringent Response Reduce Virulence and Increase Resistance to Innate Immune Responses in Staphylococcus aureus. Journal of Infectious Diseases, 2013, 207, 929-939.	4.0	94
114	Carbapenem resistance in <i>Acinetobacter baumannii</i> : laboratory challenges, mechanistic insights and therapeutic strategies. Expert Review of Anti-Infective Therapy, 2013, 11, 395-409.	4.4	120
115	The Complete Genome and Phenome of a Community-Acquired Acinetobacter baumannii. PLoS ONE, 2013, 8, e58628.	2.5	93
116	The Functions of Mediator in Candida albicans Support a Role in Shaping Species-Specific Gene Expression. PLoS Genetics, 2012, 8, e1002613.	3.5	50
117	Serine/Threonine Phosphatase Stp1 Contributes to Reduced Susceptibility to Vancomycin and Virulence in Staphylococcus aureus. Journal of Infectious Diseases, 2012, 205, 1677-1687.	4.0	98
118	Mitochondrial Sorting and Assembly Machinery Subunit Sam37 in Candida albicans: Insight into the Roles of Mitochondria in Fitness, Cell Wall Integrity, and Virulence. Eukaryotic Cell, 2012, 11, 532-544.	3.4	57
119	The role of horizontal gene transfer in the dissemination of extended-spectrum beta-lactamase–producing Escherichia coli and Klebsiella pneumoniae isolates in an endemic setting. Diagnostic Microbiology and Infectious Disease, 2012, 74, 34-38.	1.8	39
120	The Success of Acinetobacter Species; Genetic, Metabolic and Virulence Attributes. PLoS ONE, 2012, 7, e46984.	2.5	165
121	Surveillance of infection burden in residential aged care facilities. Medical Journal of Australia, 2012, 196, 327-331.	1.7	49
122	Whole Genome Characterization of the Mechanisms of Daptomycin Resistance in Clinical and Laboratory Derived Isolates of Staphylococcus aureus. PLoS ONE, 2012, 7, e28316.	2.5	202
123	Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. International Journal of Antimicrobial Agents, 2011, 37, 26-32.	2.5	66
124	Insights into <i>Acinetobacter baumannii</i> pathogenicity. IUBMB Life, 2011, 63, 1055-1060.	3.4	151
125	The Interface Between Antibiotic Resistance and Virulence in Staphylococcus aureus and Its Impact Upon Clinical Outcomes. Clinical Infectious Diseases, 2011, 53, 576-582.	5.8	75
126	Medically important bacterial–fungal interactions. Nature Reviews Microbiology, 2010, 8, 340-349.	28.6	507

#	Article	IF	CITATIONS
127	Reply to Lalueza et al. Journal of Infectious Diseases, 2010, 201, 312-313.	4.0	10
128	Hospital-Acquired Infections Due to Gram-Negative Bacteria. New England Journal of Medicine, 2010, 362, 1804-1813.	27.0	1,664
129	Statin Therapy and Decreased Incidence of Positive Candida Cultures Among Patients With Type 2 Diabetes Mellitus Undergoing Gastrointestinal Surgery. Mayo Clinic Proceedings, 2010, 85, 1073-1079.	3.0	21
130	Treatment of <i>Acinetobacter</i> Infections. Clinical Infectious Diseases, 2010, 51, 79-84.	5.8	315
131	Cefepime MIC Breakpoint Resettlement in Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 337-338.	3.2	5
132	<i>Candida albicans</i> Hyphal Formation and Virulence Assessed Using a <i>Caenorhabditis elegans</i> Infection Model. Eukaryotic Cell, 2009, 8, 1750-1758.	3.4	178
133	Reduced Susceptibility to Vancomycin Influences Pathogenicity in <i>Staphylococcus aureus</i> Infection. Journal of Infectious Diseases, 2009, 199, 532-536.	4.0	150
134	Interaction of <i>Candida albicans</i> with an Intestinal Pathogen, <i>Salmonella enterica</i> Serovar Typhimurium. Eukaryotic Cell, 2009, 8, 732-737.	3.4	81
135	The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ: British Medical Journal, 2009, 339, b3354-b3354.	2.3	107
136	Prophylaxis against pulmonary viral and fungal infections in solid organ transplant recipients. Current Infectious Disease Reports, 2009, 11, 209-215.	3.0	2
137	<i>Galleria mellonella</i> as a Model System To Study <i>Acinetobacter baumannii</i> Pathogenesis and Therapeutics. Antimicrobial Agents and Chemotherapy, 2009, 53, 2605-2609.	3.2	272
138	Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infectious Diseases, The, 2009, 9, 245-255.	9.1	185
139	<i>Acinetobacter baumannii</i> : Emergence of a Successful Pathogen. Clinical Microbiology Reviews, 2008, 21, 538-582.	13.6	2,829
140	Prokaryote–eukaryote interactions identified by using <i>Caenorhabditis elegans</i> . Proceedings of the United States of America, 2008, 105, 14585-14590.	7.1	184
141	Tigecycline Efflux as a Mechanism for Nonsusceptibility in <i>Acinetobacter baumannii</i> . Antimicrobial Agents and Chemotherapy, 2007, 51, 2065-2069.	3.2	244
142	Failure of Current Cefepime Breakpoints To Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative Organisms. Antimicrobial Agents and Chemotherapy, 2007, 51, 4390-4395.	3.2	113
143	Acute Pyelonephritis: Management Steps That Remain Unresolved. Clinical Infectious Diseases, 2007, 45, 1249-1249.	5.8	2
144	Optimizing Therapy for <i>Acinetobacter baumannii</i> . Seminars in Respiratory and Critical Care Medicine, 2007, 28, 662-671.	2.1	10

#	Article	IF	CITATIONS
145	Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody. Clinical Infectious Diseases, 2007, 44, 204-212.	5.8	250
146	Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes/Metabolism Research and Reviews, 2007, 23, 3-13.	4.0	411
147	Emergence of Carbapenem Resistance inAcinetobacter baumanniiRecovered From Blood Cultures in Australia. Infection Control and Hospital Epidemiology, 2006, 27, 759-761.	1.8	34
148	Epidemiological Profile of Linezolidâ€Resistant Coagulaseâ€Negative Staphylococci. Clinical Infectious Diseases, 2006, 43, 165-171.	5.8	85
149	Modifying Antibiotic Prescribing in Primary Care. Clinical Infectious Diseases, 2006, 42, 1231-1233.	5.8	4
150	Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. Journal of Antimicrobial Chemotherapy, 2006, 59, 128-131.	3.0	216
151	OXA-58 and IMP-4 Carbapenem-Hydrolyzing β-Lactamases in an Acinetobacter junii Blood Culture Isolate from Australia. Antimicrobial Agents and Chemotherapy, 2006, 50, 399-400.	3.2	49
152	Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymes. Journal of Antimicrobial Chemotherapy, 2006, 57, 794-795.	3.0	24
153	Phenotypic Detection of Carbapenem-Susceptible Metallo-Â-Lactamase-Producing Gram-Negative Bacilli in the Clinical Laboratory. Journal of Clinical Microbiology, 2006, 44, 3139-3144.	3.9	176
154	Dissemination of the Metallo-Â-Lactamase Gene blaIMP-4 among Gram-Negative Pathogens in a Clinical Setting in Australia. Clinical Infectious Diseases, 2005, 41, 1549-1556.	5.8	186
155	Emergence of IMP-4 metallo-β-lactamase in a clinical isolate from Australia. Journal of Antimicrobial Chemotherapy, 2004, 54, 699-700.	3.0	47